Ceacam1's Role in Graft-versus-Host Disease and Graft-versus-Tumor Activity
Author Information
Author(s): Lu Sydney X., Kappel Lucy W., Charbonneau-Allard Anne-Marie, Atallah Renée, Holland Amanda M., Turbide Claire, Hubbard Vanessa M., Rotolo Jimmy A., Smith Marsinay, Suh David, King Christopher, Rao Uttam K., Yim Nury, Bautista Johanne L., Jenq Robert R., Penack Olaf, Na Il-Kang, Liu Chen, Murphy George, Alpdogan Onder, Blumberg Richard S., Macian Fernando, Holmes Kathryn V., Beauchemin Nicole, van den Brink Marcel R. M.
Primary Institution: Memorial Sloan-Kettering Cancer Center
Hypothesis
Ceacam1 regulates graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) activity after allogeneic bone marrow transplantation.
Conclusion
Ceacam1 is a key regulator of T cell activation and GVHD, suggesting that targeting it could help manage GVHD and improve GVT outcomes.
Supporting Evidence
- Ceacam1−/− T cells caused increased GVHD mortality and activation markers.
- Ceacam1-overexpressing T cells showed reduced GVHD.
- Ceacam1 regulates T cell activation and target organ damage in GVHD.
- Ceacam1−/− mice had increased mortality and intestinal damage after radiation.
- Ceacam1−/− donor T cells had enhanced graft-versus-tumor activity against A20 lymphoma.
Takeaway
Ceacam1 helps control how the immune system reacts after a bone marrow transplant, which can affect how well the body fights tumors and prevents harmful reactions.
Methodology
The study used mouse models to assess the role of Ceacam1 in regulating GVHD and GVT after allogeneic bone marrow transplantation.
Limitations
The study was conducted in mouse models, which may not fully replicate human responses.
Participant Demographics
Mice used were between 8 and 12 weeks old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website